Pacira BioSciences Inc (NASDAQ:PCRX) reported its fourth quarter and full-year 2025 financial results after the market closed on February 26, 2026. The company, a leader in non-opioid pain management, posted revenue that fell short of analyst expectations, while its bottom-line earnings also missed consensus estimates. The market's immediate reaction was negative, with shares trading down approximately 6.6% in after-hours activity.
Earnings and Revenue Versus Estimates
The company's financial performance for the final quarter of 2025 presented a mixed picture when held against Wall Street forecasts. While total revenue grew year-over-year, it did not meet the anticipated level.
- Q4 2025 Revenue: Reported at $196.9 million.
- Analyst Estimate for Q4 2025 Revenue: $204.4 million.
- Variance: Revenue missed estimates by approximately 3.7%.
The earnings picture showed a more pronounced shortfall on a non-GAAP basis, which is the metric most closely watched by investors and the one the company emphasizes.
- Q4 2025 Non-GAAP EPS: Reported at $0.57 per diluted share.
- Analyst Estimate for Q4 2025 Non-GAAP EPS: $0.92 per share.
- Variance: EPS missed estimates by approximately 38%.
For the full year 2025, total revenues were $726.4 million, a 4% increase over 2024. The company reported full-year GAAP net income of $7.0 million, or $0.16 per share, compared to a net loss in the prior year which was heavily impacted by a goodwill impairment charge.
Market Reaction and Performance Context
The negative after-hours move suggests investor disappointment with the earnings and revenue miss, particularly the significant shortfall in profitability. This reaction comes despite the company highlighting record EXPAREL sales volume growth of 7% for the quarter. Prior to the earnings release, the stock had shown modest strength over the past month, gaining about 10.8%. However, the post-earnings decline has effectively erased a portion of those recent gains, refocusing attention on the company's near-term financial execution and cost structure.
Key Highlights from the Earnings Report
Beyond the headline numbers, Pacira's management pointed to several strategic and operational achievements in 2025:
- EXPAREL Momentum: The flagship product achieved record quarterly sales of $155.8 million, driven by volume growth. Full-year EXPAREL sales reached $575.1 million, up 5% year-over-year. Management cited expanding reimbursement and commercial adoption as key drivers.
- Strategic Initiatives: The company highlighted the launch of its "5x30" strategy, which it credits for reigniting business momentum. Recent strategic moves include a partnership with LG Chem to commercialize EXPAREL in select Asian-Pacific markets and the appointment of a new board member with extensive clinical development experience.
- Share Repurchases: Pacira remained active in buying back its own stock, repurchasing 2.0 million shares for $50.0 million in Q4. For the full year, the company bought back 5.9 million shares for a total of $150.0 million.
- Increased Expenses: Operating expenses rose significantly in the quarter. Research and Development (R&D) increased due to a licensing payment, while Selling, General and Administrative (SG&A) costs were impacted by unanticipated business development and litigation expenses, compressing profitability.
Forward Guidance Versus Analyst Expectations
Looking ahead, Pacira provided financial guidance for the full year 2026. This outlook offers a point of comparison against existing analyst consensus, which had been modeling higher figures.
- 2026 Revenue Guidance: The company expects total revenue between $745 million and $770 million.
- Analyst Estimate for 2026 Revenue: $806.0 million.
- Context: The company's revenue guidance midpoint of $757.5 million is approximately 6% below the current analyst consensus, potentially contributing to the negative market sentiment.
The company also guided for EXPAREL net product sales in the range of $600 to $620 million and provided expectations for non-GAAP gross margins and operating expenses.
The quarterly results underscore the challenges Pacira faces in balancing growth investments with profit delivery. While the core EXPAREL franchise continues to show steady growth and the company is executing on strategic partnerships, the misses on both quarterly earnings and the subsequent below-consensus annual guidance have given investors pause. The focus will now shift to the company's ability to manage its cost structure and translate its strategic initiatives into accelerated top-line growth that meets or exceeds market expectations.
For a detailed look at upcoming earnings dates and a complete history of analyst estimates for Pacira BioSciences, visit the earnings and estimates page for PCRX.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy or sell any security. The data presented is based on publicly available information and analyst estimates, which are subject to change. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
